Feeling fine in general, allergy symptoms improved. C. T. Have been doing a lot better. Lisa L. So far, so good. Andy G. Felt congested, but improved. Richard R. Feeling fine. No problems. Roland H. Feel OK as far as allergies. Angel P. I felt relief after the treatment, and still feeling better. A. V. I feel OK, but have a little congestion. Carlin R. Feel better than before. Art P. Feel good - continue with sinusitis Bob M. Feeling moderate. Gustavo M. Much better. free Alejandro M. What Patients Said After More Than Two Months All my symptoms seem to have gone. Margareth Z. For the first time after taking the treatment, I felt like my life was my own. After 20 years I was able to go out in traffic and high winds with little or no bad effects. I could even tolerate gas lawn mowers. I was able to walk around without huffing samples and puffing. Pain in throat and lungs disappeared. Getting air in lungs.

In 1990 study in San Diego, CA the 5 active subjects with allergic rhinitis had a lowered total serum IgE from Day 0 to Day 90 while 4 placebo subjects, (2 with allergic rhinitis, 1 with asthma and 1 with both), had flat or increased IgE levels.4 In a randomized, double-blind, placebo controlled study of symptoms and serum IgE levels in San Diego, CA in mid-1991, subjects had allergic rhinitis and/or asthma. Serum was drawn at Day 0 and Day 30. Seven of the 10 active treated subjects had a reduction in total serum IgE levels. In 10 placebo treated subjects, 5 had levels of total serum IgE that stayed the same (plus or minus free 5%), 3 decreased and 2 increased.5 Statistical analysis of the open-label study as well as the double-blind randomized placebo controlled study have shown a significant effect of vitamin B12 in lowering serum IgE concentrations.

Patients gave blood serum samples prior to the treatment in 1992 and one year later in 1993. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran samples T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=34) had on average a greater reduction in IgE than the placebo group (n=33).7 On August 14, 1996 representatives of Broncorp, Inc. met with the Division Director, Dr. John Jenkins, and 14 other FDA officials of the Pulmonary Division at a PreNDA meeting. Dr. Mansfield made a presentation on the 1995 study data (n=165) from Oregon, Washington and Idaho. He noted that together the data failed to show statistical superiority of vitamin B12 on the primary free endpoint. He noted that in Washington and Idaho, during the later part of the study, there was a drop in the pollen counts and marked improvements in symptoms in both the vitamin B12 and placebo groups. (This made a therapeutic benefit of the B12 treatment difficult to demonstrate.) But samples that the pollen counts in Oregon remained higher throughout free the study and that the data from Oregon showed a significant difference between the active and placebo groups.8